Calico, Google 's anti-aging subsidiary, has announced disappointing results from its first-ever drug trial. The experimental ...

Calico's drug, called fosigotifator, is one of a handful run through a clinical trial platform at Massachusetts General Hospital, which disclosed fosigotifator's topline study results Monday.

Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google's parent company Alphabet, failed to meet its primary endpoint ...

Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease that affects nerve cells in the brain and spinal cord and leads to paralysis.

Google’s (GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug. Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal ...

Massachusetts General Hospital found neither AbbVie and Calico’s fosigotifator nor Denali’s DNL343 significantly slowed disease progression, causing misses on their respective primary endpoints.

(Cell Reports) Topline results from a HEALEY platform trial showed that fosigotifator, an investigational eIF2B activator developed by the longevity company Calico Life Sciences in collaboration ...

The first data have now emerged from a drug Calico developed. It failed. The pill, known as fosigotifator, was not designed to slow aging itself. The Food and Drug Administration does not consider ...